Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H34O11 |
| Molecular Weight | 534.5523 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1OC)[C@@H]2OC[C@H]3[C@@H]2CO[C@@H]3C4=CC=C(O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(OC)=C4
InChI
InChIKey=KFFCKOBAHMGTMW-LGQRSHAYSA-N
InChI=1S/C27H34O11/c1-32-17-6-4-13(8-19(17)33-2)25-15-11-36-26(16(15)12-35-25)14-5-7-18(20(9-14)34-3)37-27-24(31)23(30)22(29)21(10-28)38-27/h4-9,15-16,21-31H,10-12H2,1-3H3/t15-,16-,21+,22+,23-,24+,25-,26+,27+/m0/s1
| Molecular Formula | C27H34O11 |
| Molecular Weight | 534.5523 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/23122079 | https://www.ncbi.nlm.nih.gov/pubmed/23751215Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27323762 https://www.ncbi.nlm.nih.gov/pubmed/24995500
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23122079 | https://www.ncbi.nlm.nih.gov/pubmed/23751215
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27323762 https://www.ncbi.nlm.nih.gov/pubmed/24995500
Phillyrin, an active ingredient found in many medicinal plants and certain functional foods, elicits anti-obesity and anti-inflammatory properties in vivo. Phillyrin is one of the main chemical constituents of Forsythia suspensa (Thunb.), which has shown to be an important traditional Chinese medicine. Phillyrin, has being shown to possess various bioactivities, including anti-inflammatory, anti-oxidant, and antiviral activities. It has being reported that Phillyrin attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of LKB1/AMP-activated protein kinase-dependent signalling.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL613740 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27323762 |
|||
Target ID: GO:0006954 |
18.9 µM [IC50] | ||
Target ID: CHEMBL2096907 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23122079 |
|||
Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11345691 |
45.6 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Phillyrin, a natural lignan, attenuates tumor necrosis factor α-mediated insulin resistance and lipolytic acceleration in 3T3-L1 adipocytes. | 2014-07 |
|
| Phillyrin attenuates LPS-induced pulmonary inflammation via suppression of MAPK and NF-κB activation in acute lung injury mice. | 2013-10 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27323762
i.p., 10 or 20 mg/kg/day for 3 days
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11345691
Phillyrin inhibits release of the cyclo-oxygenase metabolites prostaglandin E2 (IC50 value 45.6 uM) and to a lesser extent reducing thromboxane B2 levels (IC50 value 168 uM) in human platelets
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:19:30 GMT 2025
by
admin
on
Mon Mar 31 22:19:30 GMT 2025
|
| Record UNII |
VE9P4964MG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m8704
Created by
admin on Mon Mar 31 22:19:30 GMT 2025 , Edited by admin on Mon Mar 31 22:19:30 GMT 2025
|
PRIMARY | Merck Index | ||
|
Phillyrin
Created by
admin on Mon Mar 31 22:19:30 GMT 2025 , Edited by admin on Mon Mar 31 22:19:30 GMT 2025
|
PRIMARY | |||
|
487-41-2
Created by
admin on Mon Mar 31 22:19:30 GMT 2025 , Edited by admin on Mon Mar 31 22:19:30 GMT 2025
|
PRIMARY | |||
|
DTXSID40197589
Created by
admin on Mon Mar 31 22:19:30 GMT 2025 , Edited by admin on Mon Mar 31 22:19:30 GMT 2025
|
PRIMARY | |||
|
VE9P4964MG
Created by
admin on Mon Mar 31 22:19:30 GMT 2025 , Edited by admin on Mon Mar 31 22:19:30 GMT 2025
|
PRIMARY | |||
|
300000044122
Created by
admin on Mon Mar 31 22:19:30 GMT 2025 , Edited by admin on Mon Mar 31 22:19:30 GMT 2025
|
PRIMARY | |||
|
101712
Created by
admin on Mon Mar 31 22:19:30 GMT 2025 , Edited by admin on Mon Mar 31 22:19:30 GMT 2025
|
PRIMARY |